- Home
- DNTH vs GPI Comparison
DNTH vs GPI Comparison
Compare DNTH & GPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNTH | GPI |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.0B |
| IPO Year | 2018 | 1997 |
Fundamental Metrics
Financial Performance| Metric | DNTH | GPI |
|---|---|---|
| Price | $88.63 | $332.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | $121.00 | ★ $447.14 |
| AVG Volume (30 Days) | ★ 523.2K | 112.8K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.57% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 10.85 |
| Revenue | $2,036,000.00 | ★ $11,123,721,000.00 |
| Revenue This Year | N/A | $3.41 |
| Revenue Next Year | $29.48 | $3.10 |
| P/E Ratio | ★ N/A | $32.28 |
| Revenue Growth | N/A | ★ 2.17 |
| 52 Week Low | $16.77 | $292.44 |
| 52 Week High | $96.50 | $488.39 |
Technical Indicators
Market Signals| Indicator | DNTH | GPI |
|---|---|---|
| Relative Strength Index (RSI) | 56.27 | 44.72 |
| Support Level | $33.94 | $322.01 |
| Resistance Level | $96.50 | $350.94 |
| Average True Range (ATR) | 4.02 | 14.83 |
| MACD | -1.21 | -0.39 |
| Stochastic Oscillator | 45.82 | 11.60 |
Price Performance
Historical ComparisonAbout DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
About GPI Group 1 Automotive Inc.
Group 1 owns and operates 32 collision centers and 254 automotive dealerships in the US and the UK, offering 36 brands of automobiles altogether. Slightly over half of the stores are in the US with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 31.6% of new-vehicle unit volume in 2025 and the UK 27.6%. Texas, Massachusetts, and California combined was 45.4%. Revenue in 2025 totaled $22.6 billion. The firm entered the UK in 2007 and has 109 stores there contributing about 26% of total revenue. Group 1 was founded in 1995 and is based in Houston.